Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms

Histiocytoses are clonal hematopoietic disorders frequently driven by mutations mapping to the BRAF and MEK1 and MEK2 kinases. Currently, however, the developmental origins of histiocytoses in patients are not well understood, and clinically meaningful therapeutic targets outside of BRAF and MEK are undefined. In this study, we uncovered activating mutations in CSF1R and rearrangements in RET and ALK that conferred dramatic responses to selective inhibition of RET (selpercatinib) and crizotinib, respectively, in patients with histiocytosis. Inhibition of CSF-1R with recurrent activating alterations and other actionable targets identified by genomic sequencing elicits clinical activity in patients with histiocytosis.
Author(s): Benjamin H. Durham [sup.1] [sup.2] , Estibaliz Lopez Rodrigo [sup.3] [sup.4] , Jennifer Picarsic [sup.5] [sup.6] , David Abramson [sup.7] , Veronica Rotemberg [sup.8] , Steven De Munck [sup.9] [...]